ClinicalTrials.gg
RecruitingNCT07734311Updated Aug 31, 2026

A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)

A Phase 3 interventional study of Ecnoglutide Injection and placebo with matching volume in Knee Osteoarthritis and Obesity, sponsored by Hangzhou Sciwind Biosciences Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Hangzhou Sciwind Biosciences Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 136 studies in Osteoarthritis, Knee with a site in China — 32 open to participants now, 32 under way, 4 of them phase 3. Osteoarthritis, Knee · China.

Planned enrollment
17th of 115
360 · median 100
Started
2026
with 11 others
Phase 3
14 of 136
4 open now
Primary completion
2028-05
later than 30 of 31 live
Registered
132nd of 136
by date

Among the 136 studies in Osteoarthritis, Knee with a site in China, this one is the 17th largest by planned enrollment of the 115 interventional ones that give a count, is one of 12 that started in 2026, is one of 14 in phase 3, reaches primary completion later than 30 of the 31 other live ones, and was the 132nd registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

32 of the 136 studies in Osteoarthritis, Knee with a site in China are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 136 studies in Osteoarthritis, Knee with a site in China, or all of them as a file.
02

Study summary

The main purpose of the study is to evaluate the efficacy and safety of ecnoglutide injections versus placebo in obese participants with KOA.

Read the detailed description

In this Phase III study, eligible participants will be randomized into one of the two cohorts in a 1:1 ratio to receive once-weekly subcutaneous ecnoglutide injection or placebo, including a dose-escalation period, with the total treatment duration of up to 68 weeks, plus 5 weeks of follow-up period. The overall study will last for 73 weeks.

03

Conditions studied

  • Knee Osteoarthritis
  • Obesity

Keywords

  • Ecnoglutide
  • KOA
  • Obesity
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (BMI) ≥ 28.0 kg/m\^2;
  2. The target knee must meet the diagnostic criteria of American College of Rheumatology (ACR) for knee osteoarthritis (clinical and radiological), with moderate radiographic changes (Kellgren-Lawrence grade 2 or 3). The target knee is defined as the knee with the most symptomatic knee at screening period; if pain in both knees are equal, the target knee will be the most dominant leg (preferred leg);
  3. Prior to screening, target knee pain lasting more than 12 weeks, and according to participant's self-report or medical history at screening, target knee pain lasting more than 15 days in the past month;
  4. At screening and prior to randomization, WOMAC pain score (NRS 0-10) of the target knee must be between 4 and 9 (to avoid bias in reporting, participants must not be informed of the pain score used to determine eligibility for the study);
  5. Self-reported by the participant who has a history of unsuccessful weight loss attempt by diet and exercise.

Exclusion criteria

Exclusion Criteria:

  1. The target knee has undergone joint replacement surgery;
  2. The target knee has undergone arthroscopy within 12 months prior to screening;
  3. At the time of screening, the target knee joint has any clinical features and symptoms of other active infections or crystal-induced arthropathies, as well as any other active joint diseases that may interfere with assessment;
  4. The target knee has received intra-articular injections of hyaluronic acid, any other drugs, or biologics within 3 months prior to screening; or has undergone any procedures that result in persistent sensory loss in the target knee (e.g., ablation) within 6 months prior to screening;
  5. Has received any intramuscular or oral (investigational or marketed) within 30 days prior to screening, or has received any intra-articular corticosteroid injections (investigational or marketed) in any joint within 90 days prior to screening;
  6. History of joint instability in either knee within 12 months prior to screening, such as anterior cruciate ligament rupture or recent trauma;
  7. History of any other potentially causative and/or confounding diseases, including Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease-associated arthritis, sarcoidosis, amyloidosis, or fibromyalgia;
  8. Presence of symptomatic hip osteoarthritis at the time of screening, with the exception of those who have undergone hip replacement surgery;
  9. Conditions that may interfere with the assessment of target knee pain during screening include, but are not limited to:

    • Pain in any part of the lower limb or back equal to or more severe than the pain in the target knee;
    • Pain radiating to the knee from other areas, such as hip pain affecting the knee or radicular pain;
    • Chronic widespread pain (including neuropathic pain);
  10. Change of body weight >5% within 3 months prior to screening (selfreported);
  11. Diagnosis of diabetes (excluding gestational diabetes), or with a history of diabetic ketoacidosis or hyperosmolar state/coma
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    Ecnoglutide Injection

    Once weekly

    Drug: Ecnoglutide Injection

  • Placebo comparator
    Placebo

    Once weekly

    Drug: placebo with matching volume

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score

    Time frame: Baseline, week 68

  2. Percentage Change in Body Weight

    Time frame: Baseline, week 68

Secondary outcomes

  1. Percentage of Participants with ≥5% of Body Weight Loss

    Time frame: Baseline, week 68

  2. Percentage of Participants with ≥10% of Body Weight Loss

    Time frame: Baseline, week 68

  3. Percentage of Participants with ≥50% of Reduction in WOMAC Pain Subscale Score

    Time frame: Baseline, week 68

  4. Change in WOMAC Physical Function Subscale Score

    Time frame: Baseline, week 68

  5. Change in Short Form 36 (SF36) V2 Physical Function Subscale Score

    Time frame: Baseline, week 68

  6. Absolute Change in Body Weight

    Time frame: Baseline, week 68

  7. Percentage of Participants with ≥15% of Body Weight Loss

    Time frame: Baseline, week 68

  8. Change in WOMAC Total Score

    Time frame: Baseline, week 68

  9. Percentage of Participants with ≥50% of Reduction in WOMAC Physical Function Subscale Score

    Time frame: Baseline, week 68

  10. Change in SF36V2 Score

    Time frame: Baseline, week 68

  11. Change in PGI-S Pain and Function Score of the Target Knee Joint

    PGI-S stands for Patient Global Impressions Scale - Severity

    Time frame: Baseline, week 68

  12. Change in PGI-C Pain and Function Score of the Target Knee Joint

    PGI-C stands for Patient Global Impressions Scale - Change

    Time frame: Baseline, week 68

  13. Change in Body Mass Index (BMI)

    Time frame: Baseline, week 68

  14. Change in Walking Distance During the 6-minute Walk Test

    Time frame: Baseline, week 68

  15. Percentage of Participants Using Allowed Analgesics During Wash Out

    Time frame: Baseline, week 68

  16. Amount of Allowed Analgesics Used During Wash Out

    Amount of allowed analgesics used during wash out at end of treatment (week 68)is presented. Allowed analgesic during washout should be taken within 72 hour before the visit and prior to WOMAC assessment.

    Time frame: Baseline, week 68

  17. Percentage of Participants Using Analgesics

    Time frame: Baseline, week 68

  18. Change in Amount of Analgesics Used

    Time frame: Baseline, week 68

  19. Change in Lipid Profile

    Include triglicerides, LDL-C, HDL-C, total cholesterol

    Time frame: Baseline, week 68

  20. Change in Fasting Plasma Glucose (FPG)

    Time frame: Baseline, week 68

  21. Change in HbA1c

    Time frame: Baseline, week 68

  22. Change in Fasting Insulin

    Time frame: Baseline, week 68

  23. Change in Fasting C-peptide

    Time frame: Baseline, week 68

  24. Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)

    Time frame: Baseline, week 68

  25. Change in Blood Pressure

    Time frame: Baseline, week 68

  26. Adverse events

    Time frame: Week 1 to week 73 (EOS)

  27. Change in Patient Health Questionnaire-9 (PHQ-9) Score

    PHQ-9 questionnaire will be used to monitor status of mental health of the participants.

    Time frame: Baseline to week 73 (EOS)

  28. Change in Columbia-Suicide Severity Rating Scale (C-SSRS) Score

    C-SSRS questionnaire will be used to monitor status of mental health of the participants.

    Time frame: Baseline to week 73 (EOS)

  29. Change in Waist Circumference

    Time frame: Baseline, week 68

  30. Change in Hip Circumference

    Time frame: Baseline, week 68

  31. Change in Waist-to-hip Ratio

    Time frame: Baseline, week 68

  32. Trough Concentration of Ecnoglutide

    Time frame: Week 1 to week 73 (EOS)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for May 2028, 21 months after the start.

Of 65 industry-sponsored phase 3 interventional studies under Osteoarthritis, Knee, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 27. This study's planned 21 months is close to that.

Counting every sponsor, half of 101 studies reached it within 22 months; a quarter within 15 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2026
First posted
Jul 29, 2026
StartActual
Aug 3, 2026
Primary completionEst.
May 31, 2028
CompletionEst.
Jun 30, 2028
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07734311
Lead sponsor
Hangzhou Sciwind Biosciences Co., Ltd.
Responsible party
Sponsor
First posted
Jul 29, 2026
Start date
Aug 3, 2026
Primary completion
May 31, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Aug 31, 2026

Study contacts

Yao Li
Contact
ra@sciwindbio.com
010-67889255
Weihua XU
principal investigator · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ecnoglutide

Start the discussion